Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

Ipilimumab (1mg/kg)

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 10, 2026 · PHASE 1 TRIAL

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

ClinicalTrials.gov

Phase 1 pilot study with small enrollment (n=15) testing a novel three-drug combination in advanced neuroendocrine carcinoma; no results posted in this registry record.

PreliminaryNeuroendocrine Carcinoma Amr Mohamed MD NCT05262556

Reported

Planned enrollment15

Study phasePhase 1

Primary outcome measureAntitumor activity of NP-101 (TQ Formula) p…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support